Orchestra BioMed Holdings (OBIO) Net Cash Flow (2021 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Net Cash Flow of -$6.3 million for Q1 2026, down 61.59% year-over-year from -$16.5 million in Q1 2025, and up 13.64% quarter-over-quarter from -$7.3 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) Net Cash Flow (2021 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Net Cash Flow for 6 consecutive years, with -$6.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 61.59% year-over-year to -$6.3 million; the TTM figure through Mar 2026 stood at $10.0 million (up 301.35% YoY), while the FY2025 annual figure was $12.4 million, up 249.78% from the prior year.
- Net Cash Flow improved to -$6.3 million in Q1 2026 per OBIO's latest filing, from -$7.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $77.6 million in Q2 2022 and bottomed at -$77.2 million in Q4 2022.
- Historically, Net Cash Flow has averaged $1.1 million across 5 years, with a median of -$1.1 million in 2023.
- On a YoY basis, Net Cash Flow climbed as much as 198454.75% in 2022 and fell as far as 267668.34% in 2022.
- Orchestra BioMed Holdings' Net Cash Flow stood at -$77.2 million in 2022, then surged by 114.87% to $11.5 million in 2023, then sank by 129.13% to -$3.3 million in 2024, then plunged by 118.96% to -$7.3 million in 2025, then increased by 13.64% to -$6.3 million in 2026.
- Business Quant data shows OBIO's Net Cash Flow at -$6.3 million in Q1 2026, -$7.3 million in Q4 2025, and $23.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -7.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.90 Mn |
| Jun 30, 2026 | -7.90 Mn |
| Mar 31, 2026 | -6.32 Mn |
| Mar 31, 2026 | -6.32 Mn |
| Dec 31, 2025 | -7.32 Mn |
| Dec 31, 2025 | -7.32 Mn |
| Sep 30, 2025 | 23.26 Mn |
| Sep 30, 2025 | 23.26 Mn |
| Jun 30, 2025 | 401,000.00 |
| Jun 30, 2025 | 401,000.00 |
| Mar 31, 2025 | -3.91 Mn |
| Mar 31, 2025 | -3.91 Mn |
| Dec 31, 2024 | -3.34 Mn |
| Dec 31, 2024 | -3.34 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 389,000.00 |
| Jun 30, 2024 | 389,000.00 |
| Mar 31, 2024 | -7.24 Mn |
| Mar 31, 2024 | -7.24 Mn |